Towards a vaccine against rheumatic fever

Clinical and Developmental Immunology

Volumn 13, Issue 2-4, 2006, Pages 125-132

  Guilherme, L ^a,b   Fae K C ^a,b   Higa, F ^a,b   Chaves, L ^a,b   Oshiro, S E ^a,b   Freschi De Barros, S ^a,b   Puschel, C ^a,b   Juliano, M A ^c   Tanaka, A C ^a   Spina, G ^a   Kalil, J ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Millennium Institute   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Rheumatic fever; Streptococcus pyogenes; T and B cell protective epitopes; Vaccine

Indexed keywords

EPITOPE; IMMUNOGLOBULIN G ANTIBODY; M PROTEIN; STREPTOCOCCUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CARBOXY TERMINAL SEQUENCE; CARDITIS; CELL CULTURE; CULTURE MEDIUM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEP 2 CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; PHARYNGITIS; PRIORITY JOURNAL; RHEUMATIC FEVER; STREPTOCOCCUS PYOGENES; T LYMPHOCYTE;

ANIMALS; ANTIGENS, BACTERIAL; HUMANS; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; VACCINES, SUBUNIT;

EID: 33845609952     PISSN: 17402522     EISSN: 10292357     Source Type: Journal    
DOI: 10.1080/17402520600877026     Document Type: Article

References (32)

1. Atherton e, Sheppard RC. 1989. Solid phase peptide synthesis: A practical approach. Oxford, UK: IRL Press. p 152.
2. Batzloff MR, Yan H, Davies MR, Hartas J, Lowell GH, White G, Burt DS, Leanderson T, Good MF. 2005. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus. J Infect Dis 192(8):1450-1455.
3. Beachey EH, Stollerman GH, Johnson RH, Ofek I, Bisno AL. 1979. Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein. J Exp Med 150(4):862-877.
4. Bessen D, Fischetti VA. 1988a. Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun 56(10):2666-2672.
5. Bessen D, Fischetti VA. 1988b. Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A. J Exp Med 167(6):1945-1950.
6. Bisno AL, Rubin FA, Cleary PP, Dale JB. National Institute of Allergy and Infectious DiseasesOctober 15 2005. Prospects for a group A streptococcal vaccine: Rationale, feasibility, and obstacles - report of a National Institute of allergy and infectious diseases workshop. Clin Infect Dis Oct 15;41(8):1150-1156.
7. Brand O, Gough S, Heward J. 2005. HLA, CTLA-4 and PTPN22: The shared genetic master-key to autoimmunity? Exp Rev Mol Med 7(23):1-15.
8. Brandt ER, Sriprakash KS, Hobb RI, Hayman WA, Zeng W, Batzloff MR, Jackson DC, Good MF. 2000. New multideterminant strategy for a group A streptococcal vaccine designed for the Australian aboriginal population. Nat Med 6(4):455-459.
9. Carapetis JR, McDonald M, Wilson NJ. 2005a. Acute rheumatic fever. Lancet 366(9480):155-168.
10. Carapetis JR, Steer AC, Mulholland EK, Weber M. 2005b. The global burden of group A streptococcal diseases. Lancet Infect Dis 5(11):685-694.
11. Cunningham MW. 2000. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 13(3):470-511.
12. Cunningham MW. 2003. Autoimmunity and molecular mimicry in the pathogenesis of post-streptococcal heart disease. Front Biosci 8:s533-s543.
13. Dajani A, Taubert K, Ferrieri P, Peter G, Shulman S. 1995. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever: A statement for health professionals. Committee on rheumatic fever, endocarditis, and kawasaki disease of the council on cardiovascular disease in the young, the American heart association. Pediatrics 96(4 Pt 1):758-764.
14. Fae KC, Diefenbach da Silva D, Oshiro SE, Tanaka AC, Pomerantzeff PMA, Douay C, Charron D, Toubert A, Cunningham MW, Kalil J, Guilherme L. 2006. Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. J Immunol 176(9):5662-5670.
15. Fischetti VA, Jones KF, Hollingshead SK, Scott JR. 1988. Structure, function, and genetics of streptococcal M protein. Rev Infect Dis 10(Suppl 2):S356-S359.
16. Guilherme L, Oshiro SE, Fae KC, Cunha-Neto E, Renesto G, Goldberg AC, Tanaka AC, Pomerantzeff PM, Kiss MH, Silva C, Guzman F, Patarroyo ME, Southwood S, Sette A, Kalil J. 2001. T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun 69:5345-5351.
17. Guilherme L, Cury P, Demarchi LM, Coelho V, Abel L, Lopez AP, Oshiro SE, Aliotti S, Cunha-Neto E, Pomerantzeff PM, Tanaka AC, Kalil J. 2004. Rheumatic heart disease: Proinflammatory cytokines play a role in the progression and maintenance of valvular lesions. Am J Pathol 165:1583-1591.
18. Guilherme L, Kalil J, Cunningham M. 2006. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. Autoimmunity 39(1):31-39.
19. Guilherme L, Cunha-Neto E, Coelho V, Snitcowsky R, Pillegi F, Kalil J. 1995. Human heart-infiltrating T cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation 92:415-420.
20. Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF. 1997. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 9:1723-1733.
21. Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, Wasserman SS, Dale JB. 2004. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: Phase 1 trial. JAMA 292(6):709-715.
22. Kotloff KL, Wasserman SS, Jones KF, Livio S, Hruby DE, Franke CA, Fischetti VA. 2005. Clinical and microbiological responses of volunteers to combined intranasal and oral inoculation with a Streptococcus gordonii carrier strain intended for future use as a group A streptococcus vaccine. Infect Immun 73(4):2360-2366.
23. McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, Linden J, Fries LF, Vink PE, Dale JB. 2005. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 41(8):1114-1122.
24. Medaglini D, Pozzi G, King TP, Fischetti VA. 1995. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization. Proc Natl Acad Sci USA 92(15):6868-6872.
25. Olive C, Hsien K, Horvath A, Clair T, Yarwood P, Toth I, Good MF. 2005. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides. Vaccine 23(17-18):2298-2303.
26. Polly SM, Waldman RH, High P, Wittner MK, Dorfman A. 1975. Protective studies with a group A streptococcal M protein vaccine. II. Challenge of volenteers after local immunization in the upper respiratory tract. J Infect Dis 131(3):217-224.
27. Pruksakorn S, Currie B, Brandt E, Phornphutkul C, Hunsakunachai S, Manmontri A, Robinson JH, Kehoe MA, Galbraith A, Good MF. 1994. Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. Int Immunol 6(8):1235-1244.
28. Raizada V, Williams RC Jr, Chopra P, Gopinath N, Prakash K, Sharma KB, Cherian KM, Panday S, Arora R, Nigam M, Zabriskie JB, Husby G. 1983. Tissue distribution of lymphocytes in rheumatic heart valves as defined by monoclonal anti-T cell antibodies. Am J Med 74(1):90-96.
29. Robinson JH, Atherton MC, Goodacre JA, Pinkney M, Weightman H, Kehoe MA. 1991. Mapping T-cell epitopes in group A streptococcal type 5 M protein. Infect Immun 59:4324-4331.
30. Rosner B. 1986.Fundamentals of biostatistics. 2nd ed. Massachusetts: PWS publishers. p 33-35.
31. Shulman ST, Tanz RR, Kabat W, Kabat K, Cederlund E, Patel D, Li Z, Sakota V, Dale JB, Beall B. US Streptococcal Pharyngitis Surveillance Group 2004. Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002. Clin Infect Dis 39:325-332.
32. Vohra H, Dey N, Gupta S, Sharma AK, Kumar R, McMillan D, Good MF. 2005. M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats. Res Microbiol 156(4):575-582.